At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
STTK Shattuck Labs, Inc.
Market Closed 06-18 16:00:00 EDT
4.95
+0.21
+4.43%
盘后5.04
+0.09+1.82%
19:22 EDT
High5.08Low4.73Vol1.22M
Open4.89D1 Closing4.74Amplitude7.38%
Mkt Cap433.42MTradable Cap366.57MTotal Shares87.56M
T/O6.00MT/O Rate1.65%Tradable Shares74.05M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Shattuck Labs director Clay B. Siegall buys 62,500 common shares for $250,000
Reuters  ·  06-12
Shattuck Labs director Clay B. Siegall buys 62,500 common shares for $250,000
Shattuck Labs Prices Upsized Public Equity and Warrant Offering
TIPRANKS  ·  06-11
Shattuck Labs Prices Upsized Public Equity and Warrant Offering
BUZZ-U.S. STOCKS ON THE MOVE-Illumina, Cullinan, BorgWarner
Reuters  ·  06-11
BUZZ-U.S. STOCKS ON THE MOVE-Illumina, Cullinan, BorgWarner
BUZZ-U.S. STOCKS ON THE MOVE-Cracker Barrel, Tango Therapeutics, Chewy
Reuters  ·  06-10
BUZZ-U.S. STOCKS ON THE MOVE-Cracker Barrel, Tango Therapeutics, Chewy
BUZZ-U.S. STOCKS ON THE MOVE-Nike, Shattuck Labs, Centene
Reuters  ·  06-10
BUZZ-U.S. STOCKS ON THE MOVE-Nike, Shattuck Labs, Centene
BRIEF-Shattuck Labs, Inc. Announces Pricing Of $75 Million Public Offering At $4 Per Share
Reuters  ·  06-10
BRIEF-Shattuck Labs, Inc. Announces Pricing Of $75 Million Public Offering At $4 Per Share
Shattuck Labs prices USD 75 million follow-on stock offering at USD 4 per share
Reuters  ·  06-10
Shattuck Labs prices USD 75 million follow-on stock offering at USD 4 per share
Shattuck Labs - Prices Public Offering of 10.88 Mln Shares at $4 per Share
THOMSON REUTERS  ·  06-10
Shattuck Labs - Prices Public Offering of 10.88 Mln Shares at $4 per Share
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
GlobeNewswire  ·  06-10
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
Shattuck Labs Reports Promising Phase 1 Data for SL-325
TIPRANKS  ·  06-10
Shattuck Labs Reports Promising Phase 1 Data for SL-325
BUZZ-Shattuck Labs drops after announcing equity offering
Reuters  ·  06-10
BUZZ-Shattuck Labs drops after announcing equity offering
Shattuck Labs Launches Public Offering of Common Stock
MT Newswires Live  ·  06-10
Shattuck Labs Launches Public Offering of Common Stock
Shattuck Labs TBA Spot Secondary; price range $4.00-$4.25
TIPRANKS  ·  06-10
Shattuck Labs TBA Spot Secondary; price range $4.00-$4.25
Shattuck Labs reports Phase 1 data for SL-325 DR3 antibody, with 3.7% antidrug antibody rate
Reuters  ·  06-10
Shattuck Labs reports Phase 1 data for SL-325 DR3 antibody, with 3.7% antidrug antibody rate
Shattuck Labs announces common stock offering, no amount given
TIPRANKS  ·  06-10
Shattuck Labs announces common stock offering, no amount given
Shattuck Labs, Inc. Announces Proposed Public Offering
THOMSON REUTERS  ·  06-10
Shattuck Labs, Inc. Announces Proposed Public Offering
Shattuck Labs Is Maintained at Buy by Citigroup
Dow Jones  ·  06-09
Shattuck Labs Is Maintained at Buy by Citigroup
Shattuck Labs receives notices to exercise 50,586,483 common stock warrants, raising USD 54.9 million
Reuters  ·  06-09
Shattuck Labs receives notices to exercise 50,586,483 common stock warrants, raising USD 54.9 million
Shattuck Labs - Warrant Exercise Expected to Generate $54.9 Mln in Gross Proceeds
THOMSON REUTERS  ·  06-09
Shattuck Labs - Warrant Exercise Expected to Generate $54.9 Mln in Gross Proceeds
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
THOMSON REUTERS  ·  06-09
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
No data available

Introduction

Company Name.
Shattuck Labs, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Issue price:
--